Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Antimicrob Agents Chemother ; 68(8): e0057324, 2024 Aug 07.
Artigo em Inglês | MEDLINE | ID: mdl-39016593

RESUMO

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a serious global health crisis, resulting in millions of reported deaths since its initial identification in China in November 2019. The global disparities in immunization access emphasize the urgent need for ongoing research into therapeutic interventions. This study focuses on the potential use of molecular dihydrogen (H2) inhalation as an adjunctive treatment for COVID-19. H2 therapy shows promise in inhibiting intracellular signaling pathways associated with inflammation, particularly when administered early in conjunction with nasal oxygen therapy. This phase I study, characterized by an open-label, prospective, monocentric, and single ascending-dose design, seeks to assess the safety and tolerability of the procedure in individuals with confirmed SARS-CoV-2 infection. Employing a 3 + 3 design, the study includes three exposure durations (target durations): 1 day (D1), 3 days (D2), and 6 days (D3). We concluded that the maximum tolerated duration is at least 3 days. Every patient showed clinical improvement and excellent tolerance to H2 therapy. To the best of our knowledge, this phase I clinical trial is the first to establish the safety of inhaling a mixture of H2 (3.6%) and N2 (96.4%) in hospitalized COVID-19 patients. The original device and method employed ensure the absence of explosion risk. The encouraging outcomes observed in the 12 patients included in the study justify further exploration through larger, controlled clinical trials. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04633980.


Assuntos
COVID-19 , SARS-CoV-2 , Humanos , COVID-19/terapia , Masculino , Pessoa de Meia-Idade , Administração por Inalação , Estudos Prospectivos , Feminino , Adulto , Pandemias , Idoso , Tratamento Farmacológico da COVID-19 , Infecções por Coronavirus/tratamento farmacológico , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/virologia , Betacoronavirus
2.
J Stud Alcohol ; 37(11): 1593-9, 1976 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-1003974

RESUMO

When confronted with conflicting spatial information from their visual-auditory systems, subjects compensated for the effects of alcohol by attenuating visual information when locating the source of a sound.


Assuntos
Consumo de Bebidas Alcoólicas , Percepção Auditiva/efeitos dos fármacos , Etanol/farmacologia , Percepção Espacial/efeitos dos fármacos , Percepção Visual/efeitos dos fármacos , Adolescente , Adulto , Atenção , Feminino , Humanos , Teoria da Informação , Masculino , Placebos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa